Classification of Protein-Functionalized Lipid Nanoparticles: Preparation, Characterization, and In Vivo Delivery

Classification of Protein-Functionalized Lipid Nanoparticles: Preparation, Characterization, and In Vivo Delivery

What Are Protein-Functionalized Lipid Nanoparticles?

Protein-functionalized lipid nanoparticles are conventional four-component lipid nanoparticles carrying a defined protein or protein-derived ligand on their surface. The core does what LNPs are known for: it condenses nucleic acids or hosts hydrophobic cargo, shields it from degradation, and drives endosomal escape. The protein layer converts a particle whose biodistribution is dictated by adsorbed serum apolipoproteins into one addressed to a chosen receptor, cell type, or tissue. Structurally it is a stack of four layers: a cargo core, a lipid shell of ionizable lipid, helper phospholipid and cholesterol, a hydrated PEG spacer, and a reactive terminus that anchors the protein. Each layer constrains the next, which is why a 150 kDa immunoglobulin cannot be packed at the density of a compact engineered protein binder.

The class of protein chosen decides the manufacturing route, the analytics that will be credible, and the animal experiment that can prove targeting. Programs needing protein inside the particle rather than on it use protein encapsulation in LNPs, a separate formulation problem. BOC Sciences supplies lipid building blocks and protein conjugates for all six classes and provides nanoparticle functionalization services from ligand design through in vivo verification.

Table 1. Comparison of the six protein-functionalization classes.

ClassLigand and SizePrimary ReceptorTypical ObjectiveMain Constraint
AntibodyFull IgG, ~150 kDaCD3, CD4, CD5, CD117Immune cell engineeringOrientation, Fc clearance
TransferrinGlycoprotein, ~80 kDaTfR1 (CD71)Barrier transit, tumor uptakeEndogenous ligand competition
LactoferrinGlycoprotein, ~80 kDaLRP1, intelectin-1Brain and retinal deliveryCationic layer stability
Apolipoprotein EApolipoprotein, ~34 kDaLDLR, LRP1Hepatocyte deliveryCorona versus added protein
AlbuminPlasma protein, ~66.5 kDagp60, SPARC, FcRnStealth, lymphatic exposureDesorption, ligand masking
Engineered binderEngineered ankyrin-repeat protein binder, engineered three-helix bundle protein binder, 6-20 kDaAny validated epitopeHigh-density targetingNo Fc recycling

Antibody-Functionalized Lipid Nanoparticles

Structure and Functional Roles of Antibody-Functionalized LNPs

Antibody-functionalized LNPs carry antibodies or antibody-derived recognition domains on their external surface. The antibody acts as a targeting ligand that recognizes a specific cell-surface antigen or receptor, increasing the probability of particle association with the intended cell population. Full-length immunoglobulin G (IgG) is frequently considered because it contains two antigen-binding arms and an Fc region. Smaller formats, including Fab and single-chain variable fragments (scFv), can also be used when a more compact surface architecture is desirable.

The orientation of the antibody is a major determinant of functional performance. Ideally, its antigen-binding regions should remain exposed to the surrounding environment, while the attachment site is positioned away from the paratope. Randomly attaching antibodies through multiple accessible lysine residues may produce heterogeneous orientations, including particles in which some binding domains face the lipid surface or become sterically obstructed. Site-specific conjugation or controlled Fc-directed attachment can improve the accessibility of the antigen-binding regions.

Antibody-functionalized LNPs are particularly useful when passive LNP accumulation is insufficient to achieve selective cellular uptake. Potential targets include cell-surface receptors on endothelial cells, immune-cell populations, and tumor-associated cells. However, receptor binding alone does not guarantee productive delivery. The selected receptor should support internalization or an appropriate intracellular trafficking pathway, and the antibody should maintain sufficient affinity after surface attachment. Full-length IgG also introduces Fc-mediated interactions that may increase uptake by Fc receptor-bearing cells, creating an additional variable in biodistribution.

Preparation Methods for Antibody-Functionalized LNPs

Antibody-functionalized LNPs are commonly prepared by introducing a reactive lipid anchor into the particle and subsequently coupling the antibody to the surface. A practical starting point is to prepare the payload-containing LNP first, followed by surface conjugation under conditions that preserve the lipid structure and antibody activity.

Maleimide-Thiol Coupling: Maleimide-functionalized PEG-lipids are incorporated into the LNP formulation during particle assembly or introduced through post-insertion. Thiol groups are then introduced onto the antibody through controlled sulfhydryl modification or partial disulfide reduction. The resulting thiols react with surface maleimide groups to form stable thioether linkages. The extent of antibody reduction must be controlled because excessive disulfide cleavage can disrupt antibody structure and antigen recognition.

NHS-Ester and Amine Coupling: Activated ester groups can react with primary amines on antibody lysine residues. Alternatively, carboxyl-functionalized PEG-lipids can be activated using carbodiimide chemistry before reaction with antibody amines. These approaches are accessible and compatible with different protein structures, but they may generate heterogeneous attachment sites. When lysine residues are located near the antigen-binding region, conjugation can reduce receptor recognition.

Site-Specific Click Chemistry: Antibodies engineered with azide, alkyne, or other bioorthogonal functional groups can be attached to complementary lipid anchors through selective click reactions. This approach provides greater control over attachment position and can reduce unwanted modification of functional antibody domains.

Fc-Directed Antibody Capture: An alternative architecture uses an Fc-binding protein domain immobilized on the LNP surface to capture an antibody through its Fc region. This avoids direct chemical modification of the target antibody and can preserve the accessibility of its antigen-binding arms. A 2025 research study demonstrated this orientation-controlled strategy for targeted mRNA-LNP delivery. The approach is particularly relevant when conventional conjugation produces substantial loss of antibody affinity.

The choice of preparation method should account for antibody format, available reactive groups, particle composition, and payload sensitivity. For formulation development, conjugation conditions should be screened independently from the initial LNP assembly conditions to identify a process that preserves both nanoparticle integrity and antibody recognition.

Purification and Characterization of Antibody-Functionalized LNPs

Purification is required to remove unbound antibodies, residual coupling reagents, and soluble reaction products. Size-exclusion chromatography (SEC) separates antibody-associated nanoparticles from smaller free protein molecules according to their hydrodynamic size. Ultrafiltration and tangential flow filtration (TFF) provide alternative separation and buffer-exchange approaches, particularly when larger sample volumes are involved. The selection of a purification method should consider particle recovery, membrane adsorption, and the possibility of nanoparticle aggregation during processing.

Characterization should establish both the physical properties of the modified LNP and the functional status of the attached antibody.

Ligand density deserves particular attention. Too few antibodies may provide insufficient receptor engagement, whereas excessive surface coverage can increase steric hindrance, multivalent receptor binding, and nonspecific interactions. A 2026 study of antibody-conjugated LNPs demonstrated that the antibody-to-particle ratio influenced binding, internalization, and tissue distribution, with lower-density formulations performing better in the investigated system. This finding supports empirical density screening rather than applying a universal antibody loading value to every LNP.

In Vivo Delivery Strategies for Antibody-Functionalized LNPs

Systemic intravenous administration is frequently considered when antibody-functionalized LNPs are designed to reach receptors exposed to the circulation. After administration, the antibody must remain accessible despite interactions with plasma proteins and other biological components. Its receptor-binding activity should be maintained during circulation long enough for the particle to encounter the intended tissue.

The target receptor should be evaluated according to its surface abundance, tissue distribution, internalization behavior, and accessibility. Receptors that internalize following ligand binding are generally more suitable for intracellular payload delivery than receptors that only support stable surface attachment. For nucleic acid delivery, receptor-mediated uptake must also be followed by endosomal escape and cytosolic payload release. Strong cell-surface binding without productive intracellular trafficking may increase measured uptake while providing little functional delivery.

Full-length antibodies introduce an additional consideration: Fc-mediated interactions may change the distribution of LNPs independently of antigen recognition. Selecting an appropriate antibody format, controlling Fc exposure, and comparing intact IgG with smaller fragments can help determine whether the observed targeting is driven by the intended antigen-binding domain or by nonspecific Fc interactions.

Evaluation of In Vivo Delivery by Antibody-Functionalized LNPs

In vivo evaluation should distinguish particle accumulation from actual payload delivery. Fluorescently labeled lipids can track the carrier, while a separately measurable nucleic acid or reporter payload can provide information about cargo distribution and functional expression. Tracking only the lipid signal may overestimate delivery because labeled lipids can redistribute independently of intact nanoparticles.

Whole-body imaging provides an initial overview of particle distribution. After tissue collection, ex vivo fluorescence imaging, quantitative tissue analysis, and microscopy can identify the organs and regions containing the carrier or payload. Flow cytometry of tissue-derived cell populations can further determine whether the particles associate preferentially with the intended receptor-positive cells.

Functional delivery should be confirmed using payload-specific measurements, such as reporter protein expression, target gene knockdown, or changes in the intended intracellular biological pathway. Receptor-blocking experiments, ligand-free LNP controls, and non-targeting antibody controls help establish whether the observed effect depends on antibody-mediated recognition. For brain-directed systems, vascular perfusion and capillary-depletion analysis are particularly useful because particles retained in cerebral blood vessels should not be interpreted as successful delivery to brain parenchyma.

Table 2. Preparation and Evaluation Strategies for Antibody-Functionalized LNPs.

Preparation MethodIn Vitro VerificationDelivery RouteIn Vivo Delivery Verification
Maleimide-thiol coupling using antibody thiolation and maleimide-PEG-lipid anchorsAntibody loading, antigen binding, receptor-specific uptake, and payload expressionIntravenous administration for accessible systemic targets; local administration when appropriateWhole-body imaging, organ distribution, target-cell association, and functional payload expression
NHS-ester or EDC/NHS-mediated amine couplingConjugation efficiency, antibody integrity, antigen recognition, and cellular internalizationRoute selected according to receptor location and target tissue accessibilityComparison with ligand-free and non-targeting controls; tissue-level and cell-level payload analysis
Site-specific click chemistry or Fc-directed antibody captureBinding-domain accessibility, ligand density, receptor specificity, and functional deliveryIntravenous or target-specific local administrationReceptor-dependent biodistribution, target-cell transfection, and tissue-specific functional readouts
Developing Antibody-Functionalized LNPs for Specific Cell Targeting?

BOC Sciences provides antibody and antibody-derived materials, protein-lipid conjugation, surface density optimization, customized LNP preparation, and receptor-specific delivery evaluation.

Transferrin-Functionalized Lipid Nanoparticles

Structure and Functional Roles of Transferrin-Functionalized LNPs

Transferrin-functionalized LNPs use transferrin (Tf), an iron-binding glycoprotein, as a surface ligand for recognition of transferrin receptors. Transferrin receptor 1 (TfR1) is expressed on many metabolically active cells and is particularly relevant to brain delivery because it is present on brain microvascular endothelial cells. The interaction between transferrin and TfR1 provides a potential route for receptor-mediated endocytosis and transport across the BBB.

Transferrin exists in different iron-loading states, mainly iron-free apotransferrin and iron-bound holotransferrin. Iron loading influences its receptor-binding behavior and intracellular trafficking. After receptor recognition at the cell surface, the transferrin-receptor complex is internalized through endocytosis. The acidic endosomal environment promotes iron release, while the receptor and transferrin undergo recycling-associated trafficking. For a nanoparticle to cross an endothelial barrier, however, internalization must be followed by appropriate transcellular transport rather than permanent retention or lysosomal degradation.

Transferrin functionalization is therefore most relevant when the target tissue expresses accessible transferrin receptors and receptor-mediated uptake can improve delivery. Brain-directed nucleic acid delivery is an important research application, although transferrin receptor expression alone does not guarantee effective BBB crossing. Particle size, surface ligand density, receptor-binding avidity, and the lipid composition all contribute to the final transport outcome.

Preparation Methods for Transferrin-Functionalized LNPs

Transferrin can be attached to the LNP surface through a PEG-lipid spacer or another lipid-associated conjugation handle. A common strategy is to prepare an activated lipid-PEG intermediate and subsequently couple it to transferrin. Carboxyl-functionalized PEG-lipids can be activated using EDC/NHS chemistry to react with accessible amino groups on transferrin, generating amide-linked conjugates.

Transferrin-PEG-Lipid Conjugation: A reactive PEG-lipid is coupled to transferrin before introduction into the nanoparticle formulation. The resulting protein-lipid conjugate can be incorporated during LNP preparation or inserted into preformed particles. This strategy provides a defined spacer between the lipid surface and the receptor-binding protein.

Thiol-Maleimide Coupling: Transferrin is modified to introduce accessible sulfhydryl groups, which react with maleimide-functionalized PEG-lipids. The reaction can provide stable surface attachment, but protein modification should be controlled to avoid disrupting structural regions required for receptor recognition.

Post-Insertion: A preformed transferrin-lipid conjugate can be inserted into the surface of an existing LNP. This approach separates payload encapsulation from ligand conjugation and can reduce the exposure of sensitive cargo to protein-modification conditions. The insertion efficiency depends on lipid anchor structure, PEG length, temperature, and the composition of the original particle.

Iron-loading state should also be considered during preparation. The selected transferrin form should be consistent across comparative formulations because changes in iron saturation can influence receptor recognition and subsequent trafficking. BOC Sciences provides transferrin-conjugated lipid nanoparticle development support for evaluating these surface architectures.

Purification and Characterization of Transferrin-Functionalized LNPs

Following conjugation or post-insertion, purification is needed to separate transferrin-associated particles from unbound transferrin and residual reagents. SEC is suitable for separating nanoparticle fractions from smaller soluble proteins, while ultrafiltration and TFF can support concentration and buffer exchange. Purification conditions should be selected to minimize protein loss and particle aggregation.

DLS and PDI measurements establish whether transferrin attachment changes particle size distribution. Zeta potential analysis can reveal changes in surface charge, while TEM or cryo-EM provides morphological information. Protein quantification and electrophoretic analysis can help determine the amount of transferrin associated with the particle population.

Importantly, transferrin loading should be evaluated together with receptor-binding activity. A high protein content does not necessarily indicate that the attached transferrin is functionally accessible. Cell-free TfR binding measurements, receptor competition assays, and cellular uptake studies can determine whether the protein retains its recognition properties.

For BBB-oriented applications, an in vitro barrier model provides an additional level of evaluation. Endothelial uptake and transwell transport should be measured separately. Barrier integrity should be monitored using electrical resistance or paracellular permeability measurements so that increased particle passage is not incorrectly attributed to receptor-mediated transcytosis when it results from nonspecific barrier disruption.

In Vivo Delivery Strategies for Transferrin-Functionalized LNPs

Intravenous administration is frequently investigated for transferrin-functionalized LNPs designed to reach brain endothelial cells from systemic circulation. After entering the bloodstream, the particles encounter TfR1 on the vascular surface. Receptor recognition may promote internalization, but successful delivery to brain tissue requires the nanoparticle or its payload to move beyond the endothelial compartment.

Ligand density and receptor-binding avidity are central formulation variables. Excessive transferrin presentation can create strong multivalent attachment to endothelial receptors, potentially increasing vascular retention rather than transcytosis. In a transferrin-decorated nanoparticle study, particles with higher transferrin loading remained more strongly associated with brain endothelial cells, while lower-avidity particles showed greater ability to reach the parenchymal side. Although that study used a different nanoparticle material, it illustrates an important design consideration for receptor-targeted carriers.

The lipid composition must be optimized alongside the targeting ligand. Ionizable lipid structure, particle size, PEG-lipid content, and surface charge can influence circulation, receptor accessibility, and intracellular release. A transferrin ligand should therefore be evaluated as one component of a complete delivery system rather than as an isolated targeting solution. BOC Sciences also provides brain-targeted LNP development support for research programs requiring coordinated formulation and transport optimization.

Evaluation of In Vivo Delivery by Transferrin-Functionalized LNPs

Verification should determine whether transferrin-functionalized LNPs reach the intended tissue and deliver their payload beyond the vascular surface. Whole-body fluorescence imaging can provide an initial distribution profile, but brain-associated signal should be interpreted cautiously because it may represent particles remaining in cerebral blood vessels or endothelial cells.

Vascular perfusion before brain collection reduces the contribution of circulating particles. Capillary-depletion analysis can then separate brain vascular fractions from the parenchymal fraction, providing stronger evidence of transport beyond the endothelial compartment. Quantitative nucleic acid analysis, tissue fluorescence, and microscopy can be used together to identify the location of the carrier and its payload.

Functional delivery should be evaluated through reporter expression, target gene modulation, or another payload-specific readout in brain tissue. Receptor competition or blocking experiments can help determine whether the delivery depends on TfR-mediated recognition. The liver and spleen should also be assessed because systemic LNP administration may produce substantial distribution to these organs even when a brain-targeting ligand is present.

Table 3. Preparation and Evaluation Strategies for Transferrin-Functionalized LNPs.

Preparation MethodIn Vitro VerificationDelivery RouteIn Vivo Delivery Verification
Transferrin-PEG-lipid conjugation using activated carboxyl or amine chemistryTransferrin loading, TfR binding, cellular uptake, and barrier transportIntravenous administration for systemic receptor-mediated deliveryPerfused brain imaging, capillary depletion, brain-to-plasma distribution, and payload expression
Thiol-maleimide conjugation with controlled protein modificationProtein integrity, receptor affinity, particle stability, and transwell transportIntravenous administration or other route according to target accessibilityBrain parenchymal localization, receptor dependence, and cell-specific payload analysis
Post-insertion of preformed transferrin-lipid conjugatesInsertion efficiency, surface ligand density, barrier integrity, and functional uptakeSystemic administration with formulation-specific route optimizationBrain and peripheral organ biodistribution, vascular versus parenchymal distribution, and functional delivery
Optimizing Transferrin-Mediated LNP Delivery?

BOC Sciences supports transferrin-lipid conjugation, receptor-binding evaluation, ligand density screening, BBB-oriented LNP formulation, and targeted biodistribution studies.

Lactoferrin-Functionalized Lipid Nanoparticles

Structure and Functional Roles of Lactoferrin-Functionalized LNPs

Lactoferrin (Lf) is an iron-binding glycoprotein belonging to the transferrin family. It participates in iron transport and biological defense and has attracted interest as a targeting ligand for lipid-based nanocarriers. Lactoferrin-functionalized particles are particularly investigated for brain delivery because lactoferrin can interact with receptors on brain endothelial cells and undergo receptor-associated transport across the BBB.

The proposed transport mechanisms involve lactoferrin-recognizing receptors and, in some BBB models, contributions from low-density lipoprotein receptor-related protein 1 (LRP1). These interactions may facilitate nanoparticle association, endocytosis, and transcytosis. However, receptor expression and transport efficiency depend on the biological model and the structural presentation of lactoferrin. A single receptor pathway should not be assumed to explain all lactoferrin-mediated delivery systems.

Lactoferrin-functionalized lipid carriers are being investigated for delivery of nucleic acids, small-molecule payloads, and other compounds that have limited access to brain tissue. It is also important to distinguish conventional ionizable LNPs from solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). Some published lactoferrin studies use SLN or NLC architectures rather than standard four-component nucleic acid LNPs. Their findings support the feasibility of lactoferrin surface functionalization but do not automatically establish identical behavior in every LNP formulation.

Preparation Methods for Lactoferrin-Functionalized LNPs

Lactoferrin can be attached to lipid nanoparticles through covalent coupling, PEG-lipid-mediated conjugation, or controlled surface association. The selection depends on whether the formulation is an ionizable LNP, SLN, NLC, or another lipid-based architecture.

Carbodiimide-Mediated Coupling: Carboxyl-functionalized lipid or PEG-lipid groups can be activated using EDC/NHS chemistry and subsequently reacted with accessible amino groups on lactoferrin. This approach provides a direct route to protein attachment, although the resulting conjugate may contain different attachment orientations.

Thiol-Maleimide Conjugation: Lactoferrin is modified to introduce sulfhydryl groups, which react with maleimide-functionalized lipid anchors. The method can improve control over attachment when the reactive group is introduced at a selected protein position. Modification conditions should preserve the folded structure and receptor-recognition regions of lactoferrin.

PEG-Lipid Post-Insertion: A lactoferrin-PEG-lipid conjugate can be prepared separately and inserted into preformed particles. This modular approach allows the lipid composition and protein conjugation reaction to be optimized independently. It can also reduce the exposure of encapsulated payloads to the chemical conditions used for protein modification.

Physical adsorption may be considered for selected lipid-carrier architectures, but its stability must be evaluated under dilution and serum exposure. A protein layer that is initially detectable may desorb or rearrange after contact with biological fluids. BOC Sciences provides lactoferrin-conjugated lipid nanoparticle development support for evaluating these preparation approaches.

Purification and Characterization of Lactoferrin-Functionalized LNPs

Purification should remove free lactoferrin, soluble coupling reagents, and unreacted lipid-protein intermediates. SEC can separate nanoparticle-associated lactoferrin from unbound protein, while ultrafiltration and TFF can be used for concentration and buffer exchange. For systems prepared by physical adsorption, purification should also determine whether the protein remains associated with the particles after removal of excess ligand.

Particle size, PDI, zeta potential, and morphology should be measured before and after functionalization. DLS provides hydrodynamic size information, while TEM or cryo-EM can reveal particle morphology. Protein loading can be assessed through quantitative protein analysis, electrophoretic methods, or complementary spectroscopic measurements. FTIR can provide supporting evidence of protein-associated chemical changes, but it should not be treated as sufficient proof of preserved receptor-binding activity.

The biological integrity of lactoferrin should be assessed through receptor-binding or competition assays. If the formulation is intended for BBB delivery, an endothelial barrier model can evaluate cellular uptake and transport into the receiver compartment. Particle passage should be interpreted together with barrier integrity measurements, and payload transport should be assessed separately from the movement of the lipid carrier.

Additional testing may include encapsulation efficiency, payload release, serum stability, and the effect of protein functionalization on particle aggregation. These measurements are particularly important for SLN and NLC systems, where changes in the lipid matrix and surface layer may influence drug release and colloidal behavior.

In Vivo Delivery Strategies for Lactoferrin-Functionalized LNPs

Systemic administration is a common research route for lactoferrin-functionalized carriers intended to interact with brain endothelial receptors. Following circulation, surface-presented lactoferrin may promote receptor recognition and uptake at the BBB. Whether the carrier subsequently reaches brain parenchyma depends on receptor trafficking, nanoparticle characteristics, and the intracellular fate of the particle.

Brain targeting should be evaluated as a sequence of separate events: circulation, endothelial association, cellular internalization, transcytosis, parenchymal distribution, and payload release. An increase in endothelial uptake alone does not demonstrate that the payload has crossed the barrier. Formulations with excessive ligand density may remain associated with endothelial cells or undergo intracellular degradation rather than productive transport.

The selection of lactoferrin source, protein integrity, and surface density should be considered alongside particle size and lipid composition. Because lactoferrin can interact with more than one biological receptor or uptake pathway, the intended transport mechanism should be verified in the relevant biological model rather than inferred from the presence of the ligand.

Evaluation of In Vivo Delivery by Lactoferrin-Functionalized LNPs

In vivo evaluation should determine whether lactoferrin functionalization improves the amount of intact carrier and functional payload reaching the target tissue. Whole-body imaging can provide an initial distribution profile, while perfused organ imaging and quantitative tissue analysis can help distinguish circulating particles from tissue-associated material.

For brain-directed formulations, capillary-depletion analysis and microscopy are useful for separating vascular association from parenchymal localization. Quantitative payload measurements should be performed independently from lipid-label measurements whenever possible. For nucleic acid formulations, tissue-associated RNA quantification and reporter expression can provide complementary evidence of delivery and biological activity.

Receptor-blocking or ligand-competition experiments can help establish whether the observed delivery depends on lactoferrin recognition pathways. Comparisons with nonfunctionalized LNPs and formulations carrying an irrelevant surface protein are also useful. Evaluation should include the liver, spleen, and other major organs to identify alternative accumulation pathways and determine whether improved brain exposure is accompanied by changes in peripheral distribution.

Table 4. Preparation and Evaluation Strategies for Lactoferrin-Functionalized LNPs.

Preparation MethodIn Vitro VerificationDelivery RouteIn Vivo Delivery Verification
EDC/NHS coupling of lactoferrin to carboxyl-functionalized lipid or PEG-lipidProtein loading, structural integrity, receptor recognition, and cellular uptakeIntravenous administration for systemic brain-targeted deliveryPerfused brain imaging, capillary depletion, tissue payload quantification, and functional expression
Thiol-maleimide coupling using reactive lactoferrin and maleimide-PEG-lipidConjugation efficiency, receptor binding, particle stability, and endothelial transportSystemic administration with route selection based on target tissueBrain distribution, target-cell association, receptor dependence, and peripheral organ comparison
Post-insertion or controlled adsorption of lactoferrin-associated lipid componentsSurface retention, particle morphology, protein activity, and barrier transportIntravenous or other formulation-specific administrationCarrier and payload localization, tissue-level quantification, and functional delivery assessment
Developing Lactoferrin-Functionalized LNPs for Brain Delivery?

BOC Sciences supports lactoferrin conjugation, lipid carrier preparation, surface protein characterization, BBB-oriented formulation development, and targeted delivery evaluation.

Apolipoprotein E-Functionalized Lipid Nanoparticles

Structure and Functional Roles of ApoE-Functionalized LNPs

Apolipoprotein E (ApoE) is a lipid-binding plasma protein involved in lipoprotein transport and receptor-mediated lipid uptake. Its amphipathic structure supports interactions with lipid surfaces, while its receptor-binding regions interact with members of the low-density lipoprotein receptor (LDLR) family. These properties make ApoE an important biological component in the study of LNP biodistribution and cellular uptake.

ApoE-associated LNPs require a distinction between deliberate protein functionalization and endogenous protein corona formation. In conventional ionizable LNP systems, ApoE can adsorb onto the particle surface after exposure to biological fluids. This adsorbed ApoE may act as an endogenous targeting ligand, facilitating hepatocyte uptake through interactions with LDLR-family receptors. Consequently, an LNP that contains no preconjugated ApoE may still acquire an ApoE-associated surface state after administration.

Deliberately associating recombinant ApoE or an ApoE-derived binding domain with an LNP creates a more controlled surface design, but it does not necessarily reproduce the behavior of naturally adsorbed ApoE. Protein orientation, isoform, lipid affinity, and the stability of the association all influence receptor recognition. ApoE should therefore be regarded as a context-dependent regulator of nanoparticle disposition rather than a universal targeting ligand for every tissue.

ApoE-related LNP research is relevant to hepatic delivery and the investigation of receptor-mediated transport. Brain delivery is also explored, but ApoE adsorption can promote hepatic uptake and does not by itself establish effective BBB transcytosis. The desired organ distribution must be determined experimentally for each lipid composition and protein presentation strategy.

Preparation Methods for ApoE-Functionalized LNPs

ApoE-associated LNPs can be developed through pre-association, covalent surface conjugation, or endogenous protein recruitment. These methods produce different surface structures and should be selected according to the intended biological mechanism.

Recombinant ApoE Pre-Association: Purified ApoE can be incubated with preformed LNPs under controlled buffer and protein-to-lipid conditions. The protein associates with the lipid surface through noncovalent interactions. This approach is relatively straightforward, but the resulting association may be dynamic and susceptible to exchange with other proteins in biological fluids.

Covalent ApoE-Lipid Conjugation: ApoE can be coupled to a PEG-lipid or another lipid anchor through controlled thiol-maleimide, amine-reactive, or bioorthogonal conjugation chemistry. The resulting protein-lipid conjugate can then be incorporated into preformed particles through post-insertion or introduced during formulation development. This approach provides a more defined attachment architecture than passive adsorption.

Endogenous ApoE Recruitment: In this approach, the LNP composition is optimized to interact with ApoE naturally present in the biological environment. ApoE is not necessarily added during particle preparation. Instead, lipid composition, surface charge, and interfacial properties influence subsequent protein association. This strategy is particularly relevant to conventional ionizable LNPs and their hepatic uptake behavior.

The selected ApoE isoform and protein-to-lipid ratio should be documented during development. Different ApoE forms can exhibit different receptor-binding and lipid-association characteristics. The preparation process should also avoid conditions that cause protein aggregation or loss of its lipid-binding structure.

Purification and Characterization of ApoE-Functionalized LNPs

For pre-associated or covalently conjugated ApoE-LNPs, purification should remove unbound ApoE and residual coupling reagents. SEC can separate free protein from nanoparticle-associated protein, while TFF or ultrafiltration can be used for concentration and buffer exchange. The method should be selected according to the strength of ApoE association and the risk of protein dissociation during processing.

DLS, PDI, zeta potential, and electron microscopy should be used to characterize changes in particle size, surface charge, and morphology. ApoE association can be quantified using protein analysis or immunodetection. Where a defined ApoE-lipid conjugate is used, complementary analysis of the conjugate before and after insertion can help distinguish successful lipid-protein synthesis from simple physical adsorption.

For endogenous recruitment strategies, serum incubation studies are particularly informative. LNPs can be exposed to controlled protein-containing media, followed by separation and analysis of the associated protein fraction. Protein composition, ApoE enrichment, adsorption stability, and the influence of competing plasma proteins should be investigated. This provides a more realistic understanding of the biological surface that forms after administration.

Receptor-binding assays and cellular uptake studies can establish whether the associated ApoE remains accessible and biologically functional. These measurements should be accompanied by payload encapsulation and functional delivery analysis because increased ApoE adsorption does not necessarily produce a proportional increase in intracellular payload release.

In Vivo Delivery Strategies for ApoE-Functionalized LNPs

ApoE-associated ionizable LNPs are widely investigated in the context of hepatic delivery. Following systemic administration, ApoE adsorption can facilitate interactions with hepatic receptors and promote hepatocyte uptake. This mechanism is influenced by lipid composition and is not identical across all LNP formulations. Some lipid structures can support ApoE-associated uptake through pathways that are not completely dependent on LDLR.

For liver-directed delivery, the design objective may be to maintain sufficient ApoE association while preserving particle stability and functional payload release. The lipid composition should be screened together with ApoE binding because changing helper lipids or ionizable lipid structure can alter the protein corona and cellular uptake pathway. BOC Sciences provides liver-targeted LNP development services for formulation programs requiring systematic evaluation of hepatic distribution.

For brain-directed applications, ApoE-mediated delivery requires additional caution. The presence of ApoE on the LNP surface does not establish that the particle will undergo productive transcytosis across the BBB. Hepatic sequestration, receptor expression, ApoE isoform, and the location of the delivered payload must all be considered. A brain-targeting strategy should therefore be supported by direct evidence of parenchymal delivery rather than total brain-associated signal alone.

Evaluation of In Vivo Delivery by ApoE-Functionalized LNPs

Evaluation should establish whether ApoE association changes organ distribution, receptor dependence, and functional payload delivery. Whole-body imaging and quantitative organ analysis can identify major accumulation sites, while tissue-level imaging and cell separation methods can determine which cell populations receive the carrier.

ApoE-dependent mechanisms can be investigated using ApoE-deficient biological models, controlled ApoE reconstitution, or receptor-blocking experiments. These comparisons help distinguish endogenous ApoE recruitment from other pathways associated with the LNP surface. LDLR-family receptor dependence should be assessed in the context of the selected lipid composition rather than assumed from the presence of ApoE.

For brain-targeted systems, perfused brain collection and capillary-depletion analysis are needed to distinguish vascular retention from parenchymal delivery. For liver-targeted systems, hepatocyte-associated payload and functional expression should be measured alongside total liver accumulation. The final evaluation should compare the intended tissue against major off-target organs and determine whether ApoE association improves functional delivery rather than merely increasing particle retention.

Table 5. Preparation and Evaluation Strategies for ApoE-Functionalized LNPs.

Preparation MethodIn Vitro VerificationDelivery RouteIn Vivo Delivery Verification
Pre-association of recombinant ApoE with preformed LNPsApoE adsorption, receptor binding, serum stability, and cellular uptakeIntravenous administration for systemic distribution studiesOrgan distribution, ApoE-dependent uptake, and tissue-specific payload expression
Covalent ApoE-lipid conjugation followed by LNP insertionConjugate integrity, ligand density, receptor recognition, and particle stabilityIntravenous administration according to hepatic or other target requirementsReceptor-dependent tissue distribution, cell-specific uptake, and functional payload delivery
Endogenous ApoE recruitment through lipid composition and surface engineeringSerum protein association, ApoE enrichment, corona stability, and receptor-dependent uptakeSystemic administration with lipid-composition-specific route optimizationComparison of ApoE-dependent and independent distribution, including liver and brain analysis
Exploring ApoE-Associated LNPs for Organ-Selective Delivery?

BOC Sciences supports ApoE-lipid association studies, lipid composition optimization, protein corona characterization, and tissue-specific LNP delivery evaluation.

Albumin-Associated and Albumin-Coated Lipid Nanoparticles

Structure and Functional Roles of Albumin-Associated LNPs

Albumin-associated LNPs use serum albumin as an external protein component to influence nanoparticle stability, biological interactions, and tissue distribution. Albumin is an abundant plasma protein with multiple molecular binding regions and interactions with endogenous transport pathways. Depending on the preparation strategy, albumin may be physically adsorbed onto the particle, covalently attached through a lipid anchor, or recruited after administration through an albumin-binding lipid component.

These structures should be distinguished because an albumin-coated LNP and an albumin-recruiting LNP are not necessarily the same formulation. In a directly coated system, albumin is associated with the particle before administration. In an albumin-recruiting system, the LNP contains a lipid component designed to bind endogenous albumin after exposure to biological fluids. The latter approach does not require preconjugation of albumin to the nanoparticle surface.

Albumin association can influence circulation, protein corona composition, cellular recognition, and lymphatic transport. A particularly important research direction is the use of albumin-binding lipids to promote transport from peripheral injection sites into lymphatic vessels and draining lymph nodes. This strategy can change the distribution of LNPs compared with conventional formulations that enter the bloodstream and accumulate predominantly in the liver.

Albumin-functionalized systems are therefore relevant to lymphatic delivery, immune-cell exposure, and the investigation of alternative tissue distribution pathways. However, albumin adsorption does not universally improve circulation or targeting. Its effect depends on the binding architecture, protein conformation, surface accessibility, and interactions with other proteins and receptors.

Preparation Methods for Albumin-Associated LNPs

Three main preparation approaches can be considered, depending on whether the intended structure requires a preformed albumin coating or recruitment of endogenous albumin.

Physical Albumin Coating: Preformed LNPs can be incubated with albumin under controlled pH, ionic strength, protein concentration, and incubation conditions. Albumin associates with the particle through noncovalent interactions. The process is relatively simple, but adsorption strength and protein orientation may vary with lipid composition and buffer conditions.

Covalent Albumin Conjugation: Albumin can be coupled to activated PEG-lipids or other surface anchors through amine-reactive, thiol-reactive, or bioorthogonal chemistry. A lipid-PEG spacer can help maintain separation between the albumin structure and the particle surface, reducing steric interference with the protein's binding regions.

Albumin-Binding Lipid Incorporation: An albumin-binding lipid is incorporated into the LNP during formulation. Following administration, endogenous albumin interacts with this surface component, forming an albumin-associated nanoparticle complex. This approach is particularly relevant to lymphatic delivery research. A 2025 study demonstrated an albumin-recruiting LNP architecture in which albumin-binding lipids facilitated transport through intramuscular lymphatic vessels toward draining lymph nodes.

The third approach should not be described as direct albumin conjugation because the protein is recruited from the biological environment. This distinction affects how conjugation efficiency, protein loading, purification, and surface stability should be measured. It also determines whether albumin must be included in the initial formulation process or evaluated during subsequent biological-fluid exposure.

Purification and Characterization of Albumin-Associated LNPs

For directly coated or covalently conjugated formulations, purification should remove unbound albumin and residual reagents. SEC, ultrafiltration, and TFF can be selected according to the particle size, protein association strength, and sample volume. For albumin-recruiting formulations, characterization should instead focus on the ability of the formulated lipid surface to bind albumin after exposure to albumin-containing media.

DLS, PDI, zeta potential, and TEM or cryo-EM should be used to examine changes in particle size, surface charge, and morphology. Protein quantification can determine albumin association, while electrophoretic and spectroscopic methods can provide supporting information about protein integrity. Circular dichroism or other structural analysis may be useful when preservation of albumin conformation is important for the intended biological interaction.

Albumin association should also be evaluated under conditions that resemble the intended biological environment. Incubation with albumin-containing media can reveal whether the protein remains associated or is displaced by competing plasma proteins. The particle should be monitored for aggregation, payload leakage, and changes in encapsulation efficiency during this process.

For albumin-binding lipid systems, the binding interaction should be measured separately from total protein adsorption. A formulation that adsorbs large quantities of albumin is not necessarily one that maintains the desired albumin-binding orientation or supports the intended transport mechanism.

In Vivo Delivery Strategies for Albumin-Associated LNPs

Albumin-recruiting LNPs designed for lymphatic delivery are commonly investigated through intramuscular or other peripheral administration routes that provide access to local lymphatic drainage. After administration, endogenous albumin can associate with the LNP surface and influence its movement through the interstitial environment and lymphatic vessels. The resulting transport pattern may increase exposure of draining lymph nodes while reducing direct entry into systemic circulation.

In the 2025 albumin-recruiting LNP study, the engineered lipid formulation supported albumin-facilitated transport through intramuscular lymphatic vessels, increased dendritic-cell internalization, and reduced liver accumulation compared with the conventional distribution pattern. This result provides direct evidence for the potential of albumin recruitment as an LNP delivery strategy, but the observed behavior should be interpreted in the context of that specific lipid architecture and administration route.

Directly albumin-coated LNPs may show different distribution patterns because their protein layer is established before administration. Their circulation, macrophage interactions, and tissue uptake depend on albumin conformation and surface coverage. Therefore, the delivery route and formulation design should be selected according to whether the intended mechanism is lymphatic transport, systemic distribution, or receptor-associated tissue uptake.

Evaluation of In Vivo Delivery by Albumin-Associated LNPs

In vivo evaluation should determine whether albumin association changes the movement of the carrier and payload through the intended transport pathway. For lymphatic delivery studies, imaging can track the injection site, local lymphatic vessels, and draining lymph nodes over time. Quantitative tissue analysis can compare LNP accumulation in lymph nodes, liver, spleen, and other relevant organs.

The carrier, albumin, and payload should ideally be measured independently. This helps distinguish intact albumin-associated LNPs from free albumin, dissociated lipid labels, and released payload. Cell-level analysis can determine whether the particles reach dendritic cells, macrophages, or other intended target populations.

Albumin-binding dependence can be investigated by comparing albumin-binding and nonbinding lipid formulations, evaluating albumin competition, or examining the effect of altered albumin availability. For payload delivery, reporter expression or another functional readout should accompany biodistribution measurements. An increase in lymph-node fluorescence alone is not sufficient to demonstrate that the encapsulated cargo has reached the intended intracellular compartment.

Table 6. Preparation and Evaluation Strategies for Albumin-Associated LNPs.

Preparation MethodIn Vitro VerificationDelivery RouteIn Vivo Delivery Verification
Physical adsorption of albumin onto preformed LNPsAlbumin loading, adsorption stability, particle size, and protein conformationIntramuscular, subcutaneous, or systemic administration according to formulation designOrgan distribution, lymph-node accumulation, and albumin-associated carrier retention
Covalent albumin-PEG-lipid conjugation followed by surface insertionConjugation efficiency, albumin integrity, colloidal stability, and payload retentionRoute selected according to the intended tissue and receptor interactionsCarrier and payload distribution, target-cell uptake, and functional expression
Incorporation of albumin-binding lipids for endogenous albumin recruitmentAlbumin-binding capacity, serum stability, protein association, and particle integrityIntramuscular or other lymphatic-accessible administration routesInjection-site drainage, lymph-node accumulation, liver distribution, and cellular payload delivery
Exploring Albumin-Associated LNPs for Lymphatic Delivery?

BOC Sciences supports albumin-binding lipid evaluation, protein surface association, LNP formulation development, and lymphatic biodistribution characterization.

Engineered Protein Binder-Functionalized Lipid Nanoparticles

Structure and Functional Roles of Engineered Protein Binder-Functionalized LNPs

Engineered protein binder-functionalized LNPs use compact protein scaffolds that have been designed or selected to recognize specific molecular targets. Representative binder formats include designed ankyrin repeat proteins, engineered three-helix bundle protein binder, and fibronectin Type III Domain-Based Protein Binders. These structures provide alternatives to conventional full-length antibodies when a smaller or more modular recognition domain is desirable.

Unlike immunoglobulin-based antibodies, many engineered protein binders do not contain an Fc region. Their recognition surfaces can be engineered to bind selected receptor domains, and their amino acid sequences can be modified to introduce defined conjugation sites. This makes them useful for investigating controlled surface presentation, especially when the binding domain must remain accessible after attachment to a PEG-lipid spacer.

The functional role of an engineered binder depends on the selected target. It may promote receptor-specific particle association, internalization, or transport across a biological barrier. However, the presence of a high-affinity binder does not automatically produce productive payload delivery. The target receptor must support an appropriate uptake pathway, and the LNP must retain sufficient endosomal escape and payload-release activity.

The LNP-specific evidence base for engineered non-antibody binders is emerging. A 2026 study demonstrated site-specific attachment of engineered ankyrin-repeat protein binders to LNPs using bioorthogonal click chemistry and showed selective in vitro nucleic acid delivery to a defined lymphocyte population. The study supports the feasibility of the surface-engineering approach, but its findings should not be interpreted as universal proof of in vivo targeting for all engineered binder formats.

Preparation Methods for Engineered Protein Binder-Functionalized LNPs

Engineered protein binders are particularly compatible with site-specific conjugation because their sequences can be designed to contain selected reactive groups. This provides an opportunity to control the attachment position and reduce modification of the target-binding surface.

Engineered Cysteine-Maleimide Coupling: A cysteine residue can be introduced at a selected position on the binder, providing a defined sulfhydryl group for reaction with maleimide-functionalized PEG-lipids. This method can improve orientation control compared with nonspecific modification of multiple accessible amino groups.

Bioorthogonal Click Chemistry: Noncanonical amino acids containing azide or other reactive functional groups can be incorporated into recombinant binders. These groups can react with complementary functionalized lipid anchors under mild conditions. For example, azide-bearing protein residues can be coupled with strained alkyne groups through copper-free click chemistry.

Preconjugation and Post-Insertion: The engineered binder can first be conjugated to a PEG-lipid and purified as a protein-lipid intermediate. The purified conjugate is subsequently inserted into preformed LNPs. This modular approach allows the binder synthesis and nanoparticle assembly steps to be optimized independently.

The attachment site should be selected according to the three-dimensional structure of the binder. Terminal attachment may provide a practical starting point, but the optimal position depends on the location of the binding surface, linker flexibility, and the orientation of the protein after insertion. Passive protein adsorption should not be assumed to produce reliable receptor specificity because adsorption may generate uncontrolled orientations and unstable ligand presentation.

Purification and Characterization of Engineered Protein Binder-Functionalized LNPs

Purification should separate free engineered binder from the protein-lipid conjugate and the final LNP population. SEC can be used for separating soluble proteins and conjugates, while TFF or ultrafiltration can support nanoparticle concentration and buffer exchange. When a protein-lipid conjugate is prepared before particle insertion, the intermediate should be characterized before it is incorporated into the LNP.

DLS, PDI, zeta potential, and electron microscopy should be used to assess the physical effects of binder insertion. Protein loading should be quantified using a method appropriate for the selected binder, and the amount of unbound protein should be determined after purification. Ligand-to-particle ratio is an important parameter because the total protein content alone does not establish how many functional binders are displayed on each particle.

Binding activity should be evaluated using recombinant target proteins, receptor-binding assays, SPR, BLI, or cell-based recognition studies. These measurements can establish whether the engineered protein retains its binding capability after conjugation. Particle stability, payload encapsulation, and functional delivery should also be compared with the corresponding nonfunctionalized LNP.

Where possible, single-particle analysis can provide additional information about the distribution of functional ligands across individual nanoparticles. This is useful because a formulation with an acceptable average protein-to-particle ratio may still contain subpopulations with very different ligand densities. The relationship between ligand density, receptor binding, and cellular delivery should therefore be investigated rather than inferred from bulk protein measurements alone.

In Vivo Delivery Strategies for Engineered Protein Binder-Functionalized LNPs

Engineered protein binder-LNPs should be designed around a clearly defined target receptor and its intracellular trafficking pathway. The selected binder must recognize an accessible extracellular region of the receptor, and the receptor should support internalization or another appropriate route for payload delivery. Compact binder structures may reduce steric interference at the particle surface, but their smaller size does not automatically guarantee better biodistribution or tissue penetration.

Ligand affinity, valency, surface density, and linker length should be optimized together. A binder with extremely strong receptor association may produce prolonged surface retention, whereas a binder with insufficient affinity may not maintain adequate particle-cell interaction. The desired balance depends on whether the delivery objective is local cell uptake, transcytosis, or tissue-specific accumulation.

Systemic administration can be investigated when the target is accessible from the circulation. Local administration may be more appropriate when the target tissue can be reached directly or when systemic distribution creates substantial off-target exposure. The optimal route should be established through comparative biodistribution and functional delivery studies rather than selected solely on the basis of receptor affinity.

Evaluation of In Vivo Delivery by Engineered Protein Binder-Functionalized LNPs

Evaluation should determine whether the engineered binder increases target-specific delivery relative to nonfunctionalized particles and whether the delivered payload remains biologically active. Whole-body imaging and quantitative tissue analysis can establish the overall distribution pattern. Tissue microscopy and flow cytometry can further determine whether the particles associate with the intended receptor-positive cell populations.

Receptor-blocking or competitive binding experiments can help establish the contribution of the engineered binder to particle uptake. Where suitable biological models are available, receptor-deficient systems can provide additional evidence of target dependence. These controls are especially important when the underlying LNP formulation already exhibits natural organ tropism.

Carrier distribution and payload function should be assessed separately. Reporter expression, target gene modulation, or another payload-specific measurement can establish whether the particle has achieved productive intracellular delivery. For barrier-targeting applications, vascular retention, endothelial uptake, transcytosis, and parenchymal localization should be distinguished. If the available evidence is limited to in vitro experiments, in vivo targeting should remain a development objective rather than a demonstrated property.

Table 7. Preparation and Evaluation Strategies for Engineered Protein Binder-Functionalized LNPs.

Preparation MethodIn Vitro VerificationDelivery RouteIn Vivo Delivery Verification
Engineered cysteine-maleimide coupling to PEG-lipid anchorsBinder loading, target recognition, receptor-specific uptake, and payload expressionIntravenous or local administration according to receptor accessibilityTarget-cell distribution, receptor dependence, and functional payload expression
Bioorthogonal click conjugation using site-specific noncanonical amino acidsConjugation specificity, binding activity, ligand density, and cellular selectivitySystemic administration for accessible targets or local administration when appropriateOrgan imaging, tissue-level localization, receptor-dependent uptake, and payload activity
Preformed protein-lipid conjugate followed by LNP post-insertionInsertion efficiency, particle stability, target binding, and functional transfectionRoute selected according to the intended target tissue and delivery mechanismCarrier and cargo distribution, target-cell specificity, and functional delivery analysis
Designing Engineered Protein Binder-Functionalized LNPs?

BOC Sciences supports recombinant protein ligand preparation, site-specific protein-lipid conjugation, customized LNP surface engineering, and receptor-specific delivery evaluation.

BOC Sciences Support for Protein-Functionalized LNP Development

Protein Ligand Selection and Protein-Lipid Conjugate Design

Selecting an appropriate protein ligand is the starting point for developing a functionalized LNP. BOC Sciences supports the evaluation of protein ligands according to target receptor expression, extracellular accessibility, receptor internalization, binding affinity, and the intended tissue distribution. Antibodies, transferrin, lactoferrin, ApoE, albumin, and engineered protein binders can be considered according to the biological requirements of the project. Our development approach considers both the protein structure and the lipid attachment architecture. Protein molecular size, available reactive groups, binding-domain location, and structural stability influence the choice of linker and conjugation chemistry. Maleimide-thiol coupling, activated ester chemistry, carbodiimide-mediated conjugation, and bioorthogonal click reactions can be evaluated according to the selected ligand.

BOC Sciences also supports the design of protein-PEG-lipid intermediates, including the selection of lipid anchors, spacer length, reactive groups, and attachment positions. Our nanoparticle conjugation services and nanoparticle surface functionalization services provide technical support for developing controlled surface architectures. The goal is to obtain a protein-lipid conjugate that maintains sufficient binding activity while providing stable and accessible presentation on the final nanoparticle surface. Comparative ligand screening can also help identify whether a full-length protein, smaller binding domain, or alternative conjugation architecture is more suitable for the intended delivery objective.

LNP Formulation, Protein Conjugation, and Preparation Optimization

Protein functionalization can change particle size, surface charge, colloidal stability, and payload retention. BOC Sciences provides formulation development support to integrate protein conjugation with the underlying lipid composition and payload requirements. The development process considers the ionizable lipid, helper phospholipid, cholesterol, PEG-lipid, and functional lipid components as an integrated formulation system. Different preparation strategies can be evaluated, including direct surface conjugation, preformed protein-lipid conjugate insertion, and controlled protein association. Microfluidic mixing and other suitable particle preparation approaches can be selected according to the desired particle characteristics and payload properties. The conjugation process can then be optimized independently or integrated into the overall formulation workflow. Key process variables include lipid ratios, total lipid concentration, aqueous and organic phase conditions, mixing parameters, buffer composition, conjugation pH, reaction time, and ligand-to-particle ratio. These parameters should be evaluated in a structured manner because changes introduced during surface modification may affect the physical characteristics established during initial LNP preparation.

BOC Sciences provides lipid nanoparticle formulation and LNP process optimization support to identify suitable formulation and preparation conditions. The development strategy can be adapted for mRNA, siRNA, ASO, plasmid DNA, and other compatible payload systems.

Protein-LNP Purification and Comprehensive Characterization

BOC Sciences supports purification and characterization of protein-functionalized LNPs to establish particle integrity, surface ligand loading, and payload retention. Depending on the particle architecture and sample volume, purification approaches may include SEC, ultrafiltration, TFF, and other suitable separation methods. The objective is to remove unbound protein and residual reaction components while maintaining nanoparticle recovery and colloidal stability. Physicochemical characterization can include hydrodynamic diameter, PDI, zeta potential, morphology, lipid composition, and encapsulation efficiency. Protein-specific analysis can evaluate conjugation efficiency, ligand-to-particle ratio, protein integrity, and receptor-binding activity. Stability assessment can further investigate aggregation, protein desorption, surface rearrangement, and payload leakage during storage or exposure to biological fluids.

Our lipid nanoparticle characterization services support the evaluation of particle size, surface properties, morphology, and payload-related characteristics. Additional in vitro nanoparticle evaluation can be used to assess receptor recognition, cellular uptake, intracellular localization, and functional payload delivery. The characterization strategy should be designed around the intended mechanism of each protein ligand. For example, antibody-functionalized LNPs require antigen-binding evaluation, transferrin and lactoferrin systems require receptor-associated transport assessment, and ApoE- or albumin-associated formulations require analysis of protein association and biological-fluid interactions. A common analytical framework can be used across these systems, but the functional assays should remain ligand-specific.

Targeted Delivery and In Vivo Biodistribution Evaluation

BOC Sciences provides support for evaluating the biological performance of protein-functionalized LNPs from cellular uptake through tissue distribution. Initial studies can compare targeted and non-targeted formulations to determine whether protein functionalization improves cell association and payload delivery. Receptor competition, ligand-blocking, and intracellular localization studies can help clarify the mechanism behind the observed effects. Nanoparticle cellular uptake testing can be used to compare particle internalization across selected cell populations and evaluate the relationship between ligand density and receptor recognition. Nanoparticle intracellular localization detection can further examine whether internalized particles remain in endosomal compartments or progress toward productive intracellular payload delivery.

For in vivo studies, imaging and quantitative tissue analysis can be combined to assess the distribution of the carrier and its payload. Nanoparticle in vivo imaging services provide support for visualizing particle distribution, while nanoparticle in vivo distribution analysis can provide quantitative information on tissue accumulation and biodistribution patterns. Depending on the intended application, evaluation may focus on brain parenchymal delivery, hepatic uptake, lymphatic transport, tumor-associated tissue distribution, or immune-cell targeting. The final assessment should integrate biodistribution, target-cell association, and functional payload readouts to determine whether protein functionalization produces a meaningful improvement over the corresponding nonfunctionalized LNP.

Table 8. Protein-functionalized LNP products and development services available from BOC Sciences.

Product or ServiceScopeTypical DeliverableInquiry
Protein-Conjugated Lipid NanoparticlesCovalent and non-covalent decoration across antibody, transferrin, lactoferrin, ApoE, albumin and engineered binder formatsConjugate batch with ligand density and binding dataInquiry
Bispecific Antibody-Targeted LNPTwo-receptor or two-epitope antibody formats, asymmetric coupling, orientation controlBispecific conjugate with dual-binding verificationInquiry
LNP PEG-Lipid Optimization ServicesMaleimide, NHS, DBCO and tetrazine anchors; spacer length 1-5 kDa; mol% titration against bindingPEG-lipid specification with coupling efficiency dataInquiry
Nanoparticle Surface Functionalization ServicesChemistry selection, orientation control, purification development, quenching of unreacted groupsConjugation process with critical parameters and specificationInquiry
Nanoparticle Analysis and Characterization ServicesSize, PDI, zeta, morphology, encapsulation, ligand density, integrity and antigen bindingConsolidated report with methods and raw dataInquiry
LNP Process OptimizationMixing parameters, addition rate, buffer exchange, continuous conjugation, batch consistencyScalable process description with comparable batchesInquiry
Nanoparticle In Vitro EvaluationReceptor expression profiling, uptake and competition assays, transwell barrier modelsCell-level evaluation report supporting candidate selectionInquiry
LNP Safety AssessmentRepeat-dose tolerability, complement activation, anti-PEG IgM and cytokine responseSafety package supporting lead selection before animal studiesInquiry

Conclusion

Protein-functionalized lipid nanoparticles provide a versatile approach to improving receptor recognition, cellular uptake, tissue targeting, and payload delivery. Different protein ligands offer distinct biological advantages: antibodies enable antigen-specific recognition, transferrin and lactoferrin support receptor-mediated transport research, ApoE influences lipoprotein receptor-associated uptake, albumin can facilitate protein-associated transport pathways, and engineered protein binders provide compact and customizable targeting domains. BOC Sciences provides relevant protein and lipid building blocks, customized protein-lipid conjugation, LNP formulation development, purification, characterization, and targeted delivery evaluation to support research teams in developing protein-functionalized LNPs tailored to their specific payloads, receptors, and delivery objectives.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code